WST
West Pharmaceutical Services Inc (WST) Q1 2026 Earnings Call Highlights: Strong Revenue Growth ...
Article Summary
HOLD- West Pharmaceutical Services Inc. (NYSE: WST) reported strong revenue growth of 21% year-over-year, with Q1 2026 revenue up 21% on a reported basis and 15% organic growth, driven by strong demand for HVP components, delivery devices, and West Vantage products.
- Operating margins expanded meaningfully, with margins expanding 350 basis points to 21.4% and adjusted EPS reaching $2.13.
- West Pharmaceutical Services, raised full-year revenue and EPS guidance, anticipating 7% to 9% organic revenue growth and $8.40-$8.75 adjusted EPS.
- Biologics delivered strong organic growth of 26%, supported by strong win rates and easing regulations, and the company repurchased 1.2 million shares for $298 million.
- Despite strong performance, the macro environment remains dynamic, requiring prudent forecasting for the rest of the year, with the company facing increased costs due to rising oil and commodity prices.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 11.3% | 25% | 50.0 ptsMeets Minimum (11.3%) - Passes screener |
| EPS Growth Next 5Y ? | 12.6% | 25% | 35.0 ptsBelow Screener (12.6%) - Modest outlook |
| Target Price Upside ? | 9.4% | 20% | 35.0 ptsBelow Screener (9.4%) - Target: $338.77 vs Current: $309.70 |
| Gross Margin % ? | 36.3% | 15% | 60.0 ptsSolid (36.3%) - Decent margins |
| Drawdown from 52-Wk High ? | -3.9% | 15% | 20.0 ptsBarely a Dip (-3.9%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About WST
- West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
- It operates in two segments, Proprietary Products and Contract-Manufactured Products.
- The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products.
- This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support.
- This segment serves biologic, generic, and pharmaceutical drug companies.
- The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
- This segment primarily serves pharmaceutical, diagnostic, and medical device companies.
- It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors.
- West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.